Royalty Pharma plc — Director's Dealing 2023

Jun 6, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Royalty Pharma plc (RPRX)
CIK: 0001802768
Period of Report: 2023-06-02

Reporting Person: Lloyd George W. (EVP, Investments & CLO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-06-02	Class A Ordinary Shares	S	92221	$33.6453	Disposed	120000	Indirect
2023-06-02	Class A Ordinary Shares	S	1686	$33.5362	Disposed	128314	Indirect
2023-06-05	Class A Ordinary Shares	S	19215	$33.5387	Disposed	109099	Indirect
2023-06-06	Class A Ordinary Shares	S	79099	$33.8158	Disposed	30000	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Class A Ordinary Shares	495860	Indirect
Class A Ordinary Shares	273960	Indirect
Class A Ordinary Shares	3000	Direct
Class A Ordinary Shares	4011	Indirect

Footnotes

F1: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.51 to $33.80 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.53 to $33.55 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.50 to $33.69 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.50 to $34.02 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.